Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18185041 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL18185005 | 0.95 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL29410360 | 0.95 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL18184944 | 0.92 | ALDH1A1 (0.51) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL16654855 | 0.85 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL18184971 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL26404317 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL18184984 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL4965091 | 0.80 | KDM4E (0.46) | KDM4EKMT2AHTTL3MBTL1 | |
| SCHEMBL18185010 | 0.77 | TSHR (0.44) | ALDH1A1KDM4EMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088382-B1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9561998-B2 | Method for producing nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3088382-A1 | METHOD FOR PRODUCING NITRO COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| WO-2014194250-A2 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIVERSITY OF CINCINNATI (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PHARMACIA CORPORATION (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050119262-A1 | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent | PHARMACIA CORPORATION (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113409-A1 | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318846-A1 | METHOD FOR PRODUCING NITRO COMPOUND | NOS1, NOS3, NOS2 | ALDH1A1 2305/4885KDM4E 1869/4885MEN1 2274/4885 |
| US-20050187278-A1 | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | ALDH1A1 987/4885KDM4E 3237/4885MEN1 2764/4885 |
| US-20050113409-A1 | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith | PTGS2, NOS2, PTGES2 | ALDH1A1 574/4885KDM4E 3655/4885MEN1 4448/4885 |
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PTGS2, PTGES2, PTGS1 | ALDH1A1 1192/4885KDM4E 2503/4885MEN1 2488/4885 |
| US-20050119262-A1 | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent | PTGS2, PTGS1, PTGES2 | ALDH1A1 1551/4885KDM4E 3400/4885MEN1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.